Dysarthria in Individuals with Parkinson's Disease: a Protocol for a Binational, Cross-sectional, Case-controlled Study in French and European Portuguese (FraLusoPark)

Overview

Journal BMJ Open

Specialty General Medicine

Date 2016 Nov 19

PMID 27856480

Citations 7

Authors

Serge Pinto

Rita Cardoso

Jasmin Sadat

Isabel Guimaraes

Celine Mercier

Helena Santos

Cyril Atkinson-Clement

Joana Carvalho

Pauline Welby

Pedro Oliveira

Mariapaola DImperio

Sonia Frota

Alban Letanneux

Marina Vigario

Marisa Cruz

Isabel Pavao Martins

Francois Viallet

Joaquim J Ferreira

Affiliations

Soon will be listed here.

Abstract

Introduction: Individuals with Parkinson's disease (PD) have to deal with several aspects of voice and speech decline and thus alteration of communication ability during the course of the disease. Among these communication impairments, 3 major challenges include: (1) dysarthria, consisting of orofacial motor dysfunction and dysprosody, which is linked to the neurodegenerative processes; (2) effects of the pharmacological treatment, which vary according to the disease stage; and (3) particular speech modifications that may be language-specific, that is, dependent on the language spoken by the patients. The main objective of the FraLusoPark project is to provide a thorough evaluation of changes in PD speech as a result of pharmacological treatment and disease duration in 2 different languages (French vs European Portuguese).

Methods And Analysis: Individuals with PD are enrolled in the study in France (N=60) and Portugal (N=60). Their global motor disability and orofacial motor functions is assessed with specific clinical rating scales, without (OFF) and with (ON) pharmacological treatment. 2 groups of 60 healthy age-matched volunteers provide the reference for between-group comparisons. Along with the clinical examinations, several speech tasks are recorded to obtain acoustic and perceptual measures. Patient-reported outcome measures are used to assess the psychosocial impact of dysarthria on quality of life.

Ethics And Dissemination: The study has been approved by the local responsible committees on human experimentation and is conducted in accordance with the ethical standards. A valuable large-scale database of speech recordings and metadata from patients with PD in France and Portugal will be constructed. Results will be disseminated in several articles in peer-reviewed journals and in conference presentations. Recommendations on how to assess speech and voice disorders in individuals with PD to monitor the progression and management of symptoms will be provided.

Trial Registration Number: NCT02753192, Pre-results.

Citing Articles

Models and Approaches for Comprehension of Dysarthric Speech Using Natural Language Processing: Systematic Review.

Alaka B, Shibwabo B JMIR Rehabil Assist Technol. 2023; 10:e44489.

PMID: 37889538 PMC: 10655903. DOI: 10.2196/44489.

Phoneme Representation and Articulatory Impairment: Insights from Adults with Comorbid Motor Coordination Disorder and Dyslexia.

Marchetti R, Pinto S, Spieser L, Vaugoyeau M, Cavalli E, El Ahmadi A Brain Sci. 2023; 13(2).

PMID: 36831753 PMC: 9954044. DOI: 10.3390/brainsci13020210.

An integrated biometric voice and facial features for early detection of Parkinson's disease.

Lim W, Chiu S, Wu M, Tsai S, Wang P, Lin K NPJ Parkinsons Dis. 2022; 8(1):145.

PMID: 36309501 PMC: 9617232. DOI: 10.1038/s41531-022-00414-8.

Effectiveness of Telerehabilitation on Motor Impairments, Non-motor Symptoms and Compliance in Patients With Parkinson's Disease: A Systematic Review.

Vellata C, Belli S, Balsamo F, Giordano A, Colombo R, Maggioni G Front Neurol. 2021; 12:627999.

PMID: 34512495 PMC: 8427282. DOI: 10.3389/fneur.2021.627999.

(Dys)Prosody in Parkinson's Disease: Effects of Medication and Disease Duration on Intonation and Prosodic Phrasing.

Frota S, Cruz M, Cardoso R, Guimaraes I, Ferreira J, Pinto S Brain Sci. 2021; 11(8).

PMID: 34439719 PMC: 8392525. DOI: 10.3390/brainsci11081100.

References

Critchley E . Letter: Peak-dose dysphonia in parkinsonism. Lancet. 1976; 1(7958):544. DOI: 10.1016/s0140-6736(76)90337-8. View

Busner J, Targum S . The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2010; 4(7):28-37. PMC: 2880930. View

Halliday G, Lees A, Stern M . Milestones in Parkinson's disease--clinical and pathologic features. Mov Disord. 2011; 26(6):1015-21. DOI: 10.1002/mds.23669. View

Braak H, Braak E, Yilmazer D, Schultz C, de Vos R, Jansen E . Nigral and extranigral pathology in Parkinson's disease. J Neural Transm Suppl. 1995; 46:15-31. View

Hartelius L, Svensson P . Speech and swallowing symptoms associated with Parkinson's disease and multiple sclerosis: a survey. Folia Phoniatr Logop. 1994; 46(1):9-17. DOI: 10.1159/000266286. View

Schneider J, Sendek S, Yang C . Relationship between Motor Symptoms, Cognition, and Demographic Characteristics in Treated Mild/Moderate Parkinson's Disease. PLoS One. 2015; 10(4):e0123231. PMC: 4407885. DOI: 10.1371/journal.pone.0123231. View

Miller N, Noble E, Jones D, Allcock L, Burn D . How do I sound to me? Perceived changes in communication in Parkinson's disease. Clin Rehabil. 2007; 22(1):14-22. DOI: 10.1177/0269215507079096. View

Skodda S, Flasskamp A, Schlegel U . Instability of syllable repetition in Parkinson's disease--influence of levodopa and deep brain stimulation. Mov Disord. 2011; 26(4):728-30. DOI: 10.1002/mds.23439. View

Jenkinson C, Peto V, Fitzpatrick R, Greenhall R, Hyman N . Self-reported functioning and well-being in patients with Parkinson's disease: comparison of the short-form health survey (SF-36) and the Parkinson's Disease Questionnaire (PDQ-39). Age Ageing. 1995; 24(6):505-9. DOI: 10.1093/ageing/24.6.505. View

10.

Gibb W, Lees A . The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988; 51(6):745-52. PMC: 1033142. DOI: 10.1136/jnnp.51.6.745. View

11.

Duez D . Segmental duration in Parkinsonian French speech. Folia Phoniatr Logop. 2009; 61(4):239-46. DOI: 10.1159/000228001. View

12.

Atkinson-Clement C, Sadat J, Pinto S . Behavioral treatments for speech in Parkinson's disease: meta-analyses and review of the literature. Neurodegener Dis Manag. 2015; 5(3):233-48. DOI: 10.2217/nmt.15.16. View

13.

Klawans H . Individual manifestations of Parkinson's disease after ten or more years of levodopa. Mov Disord. 1986; 1(3):187-92. DOI: 10.1002/mds.870010304. View

14.

Nakano K, Zubick H, TYLER H . Speech defects of parkinsonian patients. Effects of levodopa therapy on speech intelligibility. Neurology. 1973; 23(8):865-70. DOI: 10.1212/wnl.23.8.865. View

15.

Miller N, Deane K, Jones D, Noble E, Gibb C . National survey of speech and language therapy provision for people with Parkinson's disease in the United Kingdom: therapists' practices. Int J Lang Commun Disord. 2011; 46(2):189-201. DOI: 10.3109/13682822.2010.484849. View

16.

Walshe M, Peach R, Miller N . Dysarthria impact profile: development of a scale to measure psychosocial effects. Int J Lang Commun Disord. 2008; 44(5):693-715. DOI: 10.1080/13682820802317536. View

17.

Hurst H, Bolton J . Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther. 2004; 27(1):26-35. DOI: 10.1016/j.jmpt.2003.11.003. View

18.

Goberman A, Coelho C, Robb M . Phonatory characteristics of parkinsonian speech before and after morning medication: the ON and OFF states. J Commun Disord. 2002; 35(3):217-39. DOI: 10.1016/s0021-9924(01)00072-7. View

19.

Coelho M, Ferreira J . Late-stage Parkinson disease. Nat Rev Neurol. 2012; 8(8):435-42. DOI: 10.1038/nrneurol.2012.126. View

20.

Nasreddine Z, Phillips N, Bedirian V, Charbonneau S, Whitehead V, Collin I . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53(4):695-9. DOI: 10.1111/j.1532-5415.2005.53221.x. View